Clinical Trial Update: CAR-T Followed by Bispecific Antibodies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sequencing of CAR-T therapy followed by bispecific antibodies in diffuse large B-cell lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bispecific antibody therapy (bispecific antibody)
• CAR-T therapy (Chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING